Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19

Stable nebulization and muco‐trapping properties of regdanvimab/IN‐006 support its development as a potent, dose‐saving inhaled therapy for COVID‐19

Abstract The respiratory tract represents the key target for antiviral delivery in early interventions to prevent severe COVID‐19. While neutralizing monoclonal antibodies (mAb) possess considerable efficacy, their current reliance on parenteral dosing necessitates very large doses and places a subs...

Full description

Bibliographic Details
Main Authors: Morgan D. McSweeney, Ian Stewart, Zach Richardson, Hyunah Kang, Yoona Park, Cheolmin Kim, Karthik Tiruthani, Whitney Wolf, Alison Schaefer, Priya Kumar, Harendra Aurora, Jeff Hutchins, Jong Moon Cho, Anthony J. Hickey, Soo Young Lee, Samuel K. Lai
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Bioengineering & Translational Medicine
Subjects:
antiviral
COVID‐19
drug delivery
inhaled delivery
mAb
nebulization
Online Access:https://doi.org/10.1002/btm2.10391

Internet

https://doi.org/10.1002/btm2.10391

Similar Items